Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma

Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma

BackgroundMerkel cell carcinoma (MCC) is a rare but highly aggressive cutaneous malignancy. Immune checkpoint inhibition (ICI) with PD-(L)1 blockade has significantly improved treatment outcomes in metastatic disease. In patients with primary resistance to PD-(L)1 inhibition, a high overall response...

Full description

Saved in:
Bibliographic Details
Main Authors: Valerie Glutsch, Patrick Schummer, Matthias Goebeler, Anja Gesierich, Bastian Schilling
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Immunology
Subjects:
Merkel cell carcinoma
immunotherapy
resistance
relapse
ipilimumab
nivolumab
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1495004/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1495004/full

Similar Items